Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Top Page
Lifecore Biomedical
(NASDAQ:LFCR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$7.00
▲(2.79% Upside)
Lifecore Biomedical's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, high leverage, and negative cash flows. Technical analysis provides some neutral signals, but valuation remains poor due to negative earnings and lack of dividends.
Positive Factors
Business Model Strength
Lifecore's diversified revenue streams and partnerships in the healthcare sector provide a robust business model that supports long-term stability and growth.
Market Position
As a leader in its niche, Lifecore benefits from strong brand recognition and expertise, which enhances its competitive position in the growing healthcare market.
Partnerships
Strategic partnerships enhance Lifecore's product offerings and provide consistent revenue, strengthening its market presence and operational capabilities.
Negative Factors
Declining Revenue
Declining revenue growth poses a challenge to Lifecore's ability to sustain its market position and invest in future growth opportunities.
High Leverage
High leverage increases financial risk and limits flexibility, potentially affecting Lifecore's ability to invest in growth and navigate economic downturns.
Negative Cash Flow
Negative operating cash flow suggests Lifecore struggles with profitability, which could hinder its ability to fund operations and strategic initiatives.
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$264.33M
Dividend YieldN/A
Average Volume (3M)136.85K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth0.47%
EPS Growth-430.88%
CountryUS
Employees524
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding37,466,350
10 Day Avg. Volume174,474
30 Day Avg. Volume136,851
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue3.21
Enterprise Value/Gross Profit9.61
Enterprise Value/Ebitda-38.12
Forecast
1Y Price Target
$8.50Price Target Upside24.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Lifecore Biomedical Business Overview & Revenue Model
Company DescriptionLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
How the Company Makes MoneyLifecore Biomedical generates revenue through multiple streams, primarily driven by the sale of its specialized hyaluronic acid products to healthcare providers and distributors. The company has established significant partnerships with medical device companies and pharmaceutical firms, allowing it to leverage its manufacturing capabilities for contract development and manufacturing services (CDMO). This collaboration not only enhances Lifecore's product offerings but also contributes to consistent revenue through service contracts. Additionally, the company benefits from a growing demand for its aesthetic products, particularly in the cosmetic dermatology market, as consumer interest in non-surgical treatments continues to rise.
Lifecore Biomedical Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q3-2025)
| Next Earnings Date:Oct 03, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic advancements in customer partnerships, pipeline progress, and operational efficiencies, suggesting a focus on long-term growth. However, the quarter experienced a decline in revenue and a net loss, influenced by specific non-recurring adjustments and increased SG&A expenses. Overall, the sentiment reflects cautious optimism, balancing growth initiatives with current financial challenges.Q3-2025 Updates
Positive Updates
Strong Customer Engagement and Expansion
Lifecore signed multiple new agreements with both new and existing customers, including a significant partnership with a large multinational partner poised to deliver a significant inflection point in volume demand in 2027.
Pipeline Advancements Towards Commercialization
10 of Lifecore's late-stage pipeline programs are poised for potential FDA approval by 2028. Significant milestones were achieved, including a statement of work with a large multinational partner and a PPQ campaign commitment.
Operational Efficiencies and Cost Reductions
Lifecore has improved production efficiencies, reduced operational expenses, and eliminated numerous consulting relationships. Enhanced productivity in direct labor areas and improved fermentation processing efficiency were noted.
Positive Cash Flow from Operations
The company achieved positive cash flow from operations of approximately $2 million during the quarter, despite one-time non-recurring expenses.
Negative Updates
Decrease in Quarterly Revenue
Revenues for the quarter decreased by 2% to $35.2 million compared to the prior year period, primarily due to a decrease in CDMO revenues.
Net Loss Compared to Prior Year
The company recorded a net loss of $14.8 million for the quarter compared to net income of $15.6 million in the previous year, attributed to the absence of a one-time favorable adjustment.
Increased SG&A Expenses
SG&A expenses increased primarily due to litigation expenses related to an activist investor matter and a securities class action lawsuit.
Company Guidance
During Lifecore's Fiscal 2025 Third Quarter Earnings Call, the company reiterated its financial guidance for the fiscal year, projecting revenues between $126.5 million and $130 million and an adjusted EBITDA ranging from $19 million to $21 million. The third quarter revenues were $35.2 million, a 2% decrease from the previous year, primarily due to a $1.5 million decline in CDMO revenues, offset by a $1 million increase in hyaluronic acid manufacturing revenues. The company reported a net loss of $14.8 million or $0.47 per diluted share, in contrast to a net income of $15.6 million or $0.42 per diluted share the previous year. Gross profit for the quarter was $9.8 million, down from $11.9 million, with a $2 million decline attributed to lower CDMO gross profit. Selling, general, and administrative expenses slightly increased to $10.1 million, with notable litigation expenses impacting the current period. Despite these challenges, Lifecore is focused on a 12% revenue CAGR and aims to improve EBITDA margins to over 25% in coming years, supported by strategic partnerships and new business ventures.Lifecore Biomedical Financial Statement Overview
Summary
Lifecore Biomedical's financials show modest revenue growth but are hampered by significant profitability and leverage issues. High debt and negative equity raise concerns about sustainability, despite some cash flow improvements.Income Statement
Lifecore Biomedical's TTM revenue shows modest growth over the previous year, but profitability remains a concern. The company exhibits a negative EBIT and net profit margin, indicating operational challenges. Despite a slight revenue increase, the negative margins highlight potential inefficiencies or cost management issues.45
Neutral
Balance Sheet
The balance sheet reflects high leverage with a substantial debt-to-equity ratio, exacerbated by negative equity in the TTM period. The company's liabilities surpass assets, posing significant financial risks and limiting financial flexibility. The return on equity is not meaningful due to negative equity, which is a red flag for potential investors.40
Negative
Cash Flow
While Lifecore Biomedical's operating cash flow has improved in the TTM period, the free cash flow remains negative due to high capital expenditures. The operating cash flow to net income ratio is positive, indicating some operational cash generation despite net losses. However, the persistent negative free cash flow suggests ongoing capital strain.50
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 130.31M | 128.87M | 128.26M | 103.27M | 111.27M | 100.87M |
| Gross Profit | 43.59M | 40.30M | 41.85M | 27.98M | 39.07M | 38.94M |
| EBITDA | -10.99M | -38.72M | 35.60M | -35.98M | 14.23M | 7.52M |
| Net Income | -44.65M | -38.72M | 12.01M | -99.56M | -116.72M | -32.66M |
Balance Sheet | ||||||
| Total Assets | 237.69M | 239.34M | 273.70M | 255.15M | 295.44M | 502.92M |
| Cash, Cash Equivalents and Short-Term Investments | 5.42M | 8.27M | 8.46M | 19.09M | 991.00K | 1.16M |
| Total Debt | 130.34M | 132.17M | 130.36M | 112.74M | 247.78M | 215.86M |
| Total Liabilities | 235.46M | 191.91M | 219.80M | 256.99M | 187.30M | 300.14M |
| Stockholders Equity | 2.23M | 47.43M | 53.90M | 35.09M | 108.14M | 202.78M |
Cash Flow | ||||||
| Free Cash Flow | -10.74M | -13.62M | -18.14M | -55.22M | -52.53M | -8.75M |
| Operating Cash Flow | 3.21M | -206.00K | -217.00K | -34.46M | -24.40M | 15.02M |
| Investing Cash Flow | -6.96M | -6.42M | -17.92M | -4.81M | 81.77M | -12.31M |
| Financing Cash Flow | 6.09M | 6.42M | 7.51M | 39.70M | -57.02M | -3.42M |
Lifecore Biomedical Technical Analysis
Negative
6.81
Price Trends
7.47
Negative
7.36
Negative
6.89
Negative
Market Momentum
-0.03
Positive
37.41
Neutral
39.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Negative. The current price of 6.81 is below the 20-day moving average (MA) of 7.57, below the 50-day MA of 7.47, and below the 200-day MA of 6.89, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.41 is Neutral, neither overbought nor oversold. The STOCH value of 39.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFCR.
Lifecore Biomedical Risk Analysis
Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifecore Biomedical Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | 442.28M | 3.56 | -39.48% | ― | -22.74% | ― | |
60 Neutral | 489.94M | -4.82 | 13.31% | ― | -3.48% | 36.57% | |
55 Neutral | 655.68M | -7.62 | 89.60% | ― | -24.38% | -94.72% | |
51 Neutral | 189.43M | -17.66 | -73.11% | ― | -27.40% | -475.41% | |
50 Neutral | 303.43M | -14.23 | -28.27% | ― | 11.40% | 56.25% | |
46 Neutral | $264.33M | ― | -76.41% | ― | 0.47% | -430.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
LFCR
Lifecore Biomedical
6.81
1.86
37.58%
EBS
Emergent Biosolutions
8.74
1.25
16.69%
ESPR
Esperion
2.56
0.88
52.38%
AQST
Aquestive Therapeutics
5.26
0.54
11.44%
TKNO
Alpha Teknova
5.79
1.08
22.93%
DERM
Journey Medical Corp
6.90
1.18
20.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.